Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints BioSpaceOver the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) BioSpace Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize. Neuroscience Read full story Post navigation Previous: Norgine gets first EU approval for WHIM syndrome therapyNext: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
